Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management

Kevin Hoffman, Malak Husseinali, Vicky Ren

Open source

DOI
10.1016/j.jaad.2026.09.045
Published
2026-09
Container
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jaad.2026.09.045,
  title = {Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management},
  author = {Kevin Hoffman and Malak Husseinali and Vicky Ren},
  year = {2026},
  journal = {Journal of the American Academy of Dermatology},
  doi = {10.1016/j.jaad.2026.09.045},
  url = {https://doi.org/10.1016/j.jaad.2026.09.045}
}

RIS

TY  - JOUR
TI  - Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management
AU  - Kevin Hoffman
AU  - Malak Husseinali
AU  - Vicky Ren
PY  - 2026
JO  - Journal of the American Academy of Dermatology
DO  - 10.1016/j.jaad.2026.09.045
UR  - https://doi.org/10.1016/j.jaad.2026.09.045
ER  - 

APA

Hoffman, K., Husseinali, M., & Ren, V. (2026). Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.09.045

Source records